These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

858 related items for PubMed ID: 17655513

  • 1. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
    Grandinetti CA, Goldspiel BR.
    Pharmacotherapy; 2007 Aug; 27(8):1125-44. PubMed ID: 17655513
    [Abstract] [Full Text] [Related]

  • 2. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB, Coleman TA, Davis CH, Carbonell CE, Davis WB.
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [Abstract] [Full Text] [Related]

  • 3. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.
    Hiles JJ, Kolesar JM.
    Am J Health Syst Pharm; 2008 Jan 15; 65(2):123-31. PubMed ID: 18192256
    [Abstract] [Full Text] [Related]

  • 4. Sorafenib and sunitinib.
    Kim A, Balis FM, Widemann BC.
    Oncologist; 2009 Aug 15; 14(8):800-5. PubMed ID: 19648603
    [No Abstract] [Full Text] [Related]

  • 5. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
    Zhao J, Zhu Y, Zhang C, Wang X, He H, Wang H, Wu Y, Zhou W, Shen Z.
    Urol Oncol; 2013 Nov 15; 31(8):1800-5. PubMed ID: 22658883
    [Abstract] [Full Text] [Related]

  • 6. [New drugs; sunitinib and sorafenib].
    van Bronswijk H, Dubois EA, Osanto S, Cohen AF.
    Ned Tijdschr Geneeskd; 2007 Dec 29; 151(52):2888-90. PubMed ID: 18257434
    [Abstract] [Full Text] [Related]

  • 7. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.
    Garcia JA, Hutson TE, Elson P, Cowey CL, Gilligan T, Nemec C, Dreicer R, Bukowski RM, Rini BI.
    Cancer; 2010 Dec 01; 116(23):5383-90. PubMed ID: 20806321
    [Abstract] [Full Text] [Related]

  • 8. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S, Bjelogrlic SK.
    J BUON; 2007 Sep 01; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [Abstract] [Full Text] [Related]

  • 9. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
    Zimmermann K, Schmittel A, Steiner U, Asemissen AM, Knoedler M, Thiel E, Miller K, Keilholz U.
    Oncology; 2009 Sep 01; 76(5):350-4. PubMed ID: 19321976
    [Abstract] [Full Text] [Related]

  • 10. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
    Tamaskar I, Garcia JA, Elson P, Wood L, Mekhail T, Dreicer R, Rini BI, Bukowski RM.
    J Urol; 2008 Jan 01; 179(1):81-6; discussion 86. PubMed ID: 17997441
    [Abstract] [Full Text] [Related]

  • 11. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
    Bolenz C, Trojan L, Honeck P, Schöppler G, Herrmann E, Alken P, Michel MS, Häcker A.
    Aktuelle Urol; 2009 Jan 01; 40(1):31-6. PubMed ID: 19177319
    [Abstract] [Full Text] [Related]

  • 12. Kidney cancer: Does hypothyroidism predict clinical outcome?
    Rini B.
    Nat Rev Urol; 2011 Jan 01; 8(1):10-1. PubMed ID: 21116300
    [No Abstract] [Full Text] [Related]

  • 13. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer.
    Di Lorenzo G, Cartenì G, Autorino R, Bruni G, Tudini M, Rizzo M, Aieta M, Gonnella A, Rescigno P, Perdonà S, Giannarini G, Pignata S, Longo N, Palmieri G, Imbimbo C, De Laurentiis M, Mirone V, Ficorella C, De Placido S.
    J Clin Oncol; 2009 Sep 20; 27(27):4469-74. PubMed ID: 19652053
    [Abstract] [Full Text] [Related]

  • 14. Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.
    Yuasa T, Tsuchiya N, Urakami S, Horikawa Y, Narita S, Inoue T, Saito M, Yamamoto S, Yonese J, Fukui I, Nakano K, Takahashi S, Hatake K, Habuchi T.
    BJU Int; 2012 May 20; 109(9):1349-54. PubMed ID: 21883864
    [Abstract] [Full Text] [Related]

  • 15. Targeted therapy for metastatic renal cell carcinoma.
    Motzer RJ, Bukowski RM.
    J Clin Oncol; 2006 Dec 10; 24(35):5601-8. PubMed ID: 17158546
    [Abstract] [Full Text] [Related]

  • 16. [Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)].
    Siebels M, Staehler M, Hegele A, Varga Z, Oberneder R, Doehn C, Heinzer H, Deutsche Gesellschaft für Immun- und Targeted Therapie e.V. (DGFIT).
    Aktuelle Urol; 2010 Mar 10; 41(2):122-30. PubMed ID: 19937556
    [Abstract] [Full Text] [Related]

  • 17. Therapy for metastatic RCC--questions remain.
    Breau RH, Leibovich BC.
    Nat Rev Urol; 2009 Nov 10; 6(11):580-1. PubMed ID: 19890336
    [No Abstract] [Full Text] [Related]

  • 18. Recent advances in molecular targeted therapy for metastatic renal cell carcinoma.
    Mizutani Y.
    Int J Urol; 2009 May 10; 16(5):444-8. PubMed ID: 19298634
    [Abstract] [Full Text] [Related]

  • 19. Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib.
    Di Fiore F, Rigal O, Ménager C, Michel P, Pfister C.
    Br J Cancer; 2011 Dec 06; 105(12):1811-3. PubMed ID: 22095228
    [Abstract] [Full Text] [Related]

  • 20. Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma.
    Guevremont C, Alasker A, Karakiewicz PI.
    Curr Opin Support Palliat Care; 2009 Sep 06; 3(3):170-9. PubMed ID: 19528803
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.